• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics Emergency Classics

Symptom-triggered benzodiazepine treatment for alcohol withdrawal [Classics Series]

byLauren KoandAndrew Cheung, MD MBA
February 19, 2014
in Emergency Classics, General Medicine Classics, Psychiatry Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. For patients withdrawing from alcohol, a symptom-triggered pharmacologic therapy may decrease detoxification time without compromising the safety or comfort of the patient

2. Symptom-triggered individualized benzodiazephine administration reduces the intensity and duration of oxazepam use during withdrawal treatment

Original Date of Publication: May 27, 2002

Study Rundown: Fixed doses of benzodiazepine are considered the first-line pharmacologic approach when treating patients with alcohol withdrawal. In this landmark study, withdrawing patients were randomized into two groups – in the first group, patients underwent individualized treatment with oxazepam in response to withdrawal symptoms and in the second group, patients were treated with a fixed amount of oxazepam with additional doses given only as needed. It was determined that the symptom-triggered patient group not only used 6 times less oxazepam but also experienced a shorter treatment duration than did the fixed-schedule group of patients. The difference in oxazepam use was not tied to any changes in safety, withdrawal intensity or comfort level of the patients. In summary, this study supports the use of symptom-triggered benzodiazepine administration in patients suffering alcohol withdrawal.

Click to read the study in Archives of Internal Medicine

In-Depth [randomized, controlled study]: This double-blinded randomized control trial was originally published in the Archives of Internal Medicine in May of 2002. An uninvolved pharmacist randomized all 117 eligible patients admitted to the alcohol treatment inpatient program, a clinic associated with the Lausanne University hospital, into clusters of 10 participants to either the symptom-triggered or fixed schedule group. Fixed-schedule subjects received a 30 mg dose of oxazepam every 6 hours, and subsequently, 8 doses of 15 mg. Shortly after administration, patients would be administered additional drugs, depending on their Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar) score.  Symptom-triggered subjects would receive a placebo every 6 hours and were administered oxazepam only if their CIWA-Ar score reached certain pre-determined thresholds. In comparing the two groups, only 39% in the symptom-triggered group were treated with oxazepam, which stood in great contrast to the 100% treated in the fixed schedule group (P < .001). The mean total oxazepam dose administered to the symptom-triggered and fixed-schedule groups were 37.5 mg and 231.4 mg (P < .001) respectively.  The mean duration of treatment in the symptom triggered group was 20.0 hours, which was significantly lower than the mean duration time of 62.7 hours in the fixed schedule group (P < .001).

RELATED REPORTS

Heavy smoking and alcohol use may be associated with insomnia and sleep dissatisfaction

Wellness Check: Sleep

#VisualAbstract: Effectiveness of stand-alone telephone-delivered intervention for reducing problem alcohol use

Despite these differences, there were no distinctions in comfort level noted between individuals in the two groups, as measured by comparing the CIWA-Ar scores of each patient. In sum, symptom-triggered benzodiazepine treatment in alcohol withdrawal patients is safe, and can lead to a reduction in the intensity and duration of oxazepam use.

© 2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: Alcoholbenzodiazepinewithdrawal
Previous Post

Elective induction may increase risk of C-section in obese women

Next Post

Caffeine intake among youth remains stable, but sources vary

RelatedReports

E-interventions linked to short-term reduction in alcohol consumption in college students
Chronic Disease

Heavy smoking and alcohol use may be associated with insomnia and sleep dissatisfaction

November 18, 2022
Plagiocephaly/brachycephaly associated with lower cognitive and academic achievement scores
Wellness

Wellness Check: Sleep

November 17, 2022
#VisualAbstract: Dapagliflozin slows disease progression in patients with heart failure with preserved ejection fraction
StudyGraphics

#VisualAbstract: Effectiveness of stand-alone telephone-delivered intervention for reducing problem alcohol use

October 6, 2022
Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation
Chronic Disease

Pharmacotherapy is effective for acute insomnia but with worse side effect profiles than placebo

July 26, 2022
Next Post
Caffeine intake among youth remains stable, but sources vary

Caffeine intake among youth remains stable, but sources vary

Dexamethasone shows comparable efficacy to prednisone/prednisolone in pediatric asthma

Dexamethasone shows comparable efficacy to prednisone/prednisolone in pediatric asthma

Adjuvant radiotherapy reduces recurrence of ductal carcinoma; no effect on long-term prognosis

2 Minute Medicine Rewind February 3 – 10, 2014

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Efanesoctocog alfa is efficacious in treating severe hemophilia A
  • Mavacamten associated with improvement in submaximal exertional tolerance: A secondary analysis of the EXPLORER-HCM randomized trial
  • Sodium-glucose cotransporter 2 inhibitors may reduce incidence of obstructive airway disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options